Low liver fat in non‐alcoholic steatohepatitis‐related significant fibrosis and cirrhosis is associated with <scp>hepatocellular carcinoma</scp>, decompensation and mortality
Sung Won Lee(University of California San Diego), Rohit Loomba(University of California San Diego), Atsushi Nakajima(Yokohama City University), Ayşe Erden(Ankara University), Diğdem Kuru Öz(Ankara University), Daniel Q. Huang(National University of Singapore), Nabil Noureddin(University of California San Diego), Nobuharu Tamaki(The Japanese Society of Gastroenterological Surgery), Harris Siddiqi(University of California San Diego), Tarek Nayfeh(Mayo Clinic), Veeral Ajmera(University of California San Diego), Abdul M. Majzoub(Mayo Clinic), Mesut Gümüşsoy(Ankara University), Monica A. Tincopa(University of California San Diego), Ricki Bettencourt(University of California San Diego), Namiki Izumi(Musashino Red Cross Hospital), Maral Amangurbanova(University of California San Diego), R Idilman(Ankara University), Masato Yoneda(Yokohama City University), Egbert Madamba(University of California San Diego)
Cited by 24
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k